Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Oncology Letters|January 25, 2019
MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase IPengfei Zhang, Jikai Yin, Lijuan Yuan, et al.
Molecular Cell|April 17, 2026
Cytoplasmic RNase III Drosha controls lipogenesis by noncanonical regulation of SREBP1Tiejian Nie, Jianjun Lu, DouDou Dong, et al.
The American Journal of Gastroenterology|November 19, 2014
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort studyXiaobin Feng, Ruocai Xu, Xilin Du, et al.
Journal of Gastroenterology and Hepatology|October 21, 2025
The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver CirrhosisChao Fan, Xiaojun He, Yun Zhou, et al.
Surgical Endoscopy|May 16, 2025
Liver resection versus interventional treatments for hepatocellular carcinoma patients with hypohepatia: a multicenter studyShoujie Zhao, Yejing Zhu, Jinming Zhu, et al.
Frontiers in Oncology|February 13, 2023
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational studyYejing Zhu, Enxin Wang, Shoujie Zhao, et al.
International Journal of Surgery (London, England)|December 19, 2025
TIPS improves survival in patients with cirrhosis and recurrent ascites: a multicenter observational studyBo Wang, Jun Zhu, Jing Li, et al.
Frontiers in Oncology|July 12, 2023
Potential candidates for liver resection in liver-confined advanced HCC: a Chinese multicenter observational studyTingting Bai, Enxin Wang, Shoujie Zhao, et al.
The Lancet. Oncology|May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Pageof 5